Related Experiment Video

Updated: Jun 1, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma

Joseph Gera1, Alan Lichtenstein

  • 1Division of Hematology-Oncology, Greater Los Angeles VA Healthcare Center, UCLA School of Medicine, Los Angeles, CA 90073, USA.

Leukemia & Lymphoma
|May 24, 2011
PubMed

Insights

Targeting the mammalian target of rapamycin (mTOR) pathway is crucial for cancer therapy. New inhibitors targeting both mTORC1 and mTORC2 complexes show promise, especially in myeloma models, with DEPTOR emerging as a potential therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The mammalian target of rapamycin (mTOR) pathway is a central regulator of cell growth, proliferation, metabolism, and survival.
  • mTOR plays a critical role in tumorigenesis, making it a key target for cancer therapies.
  • Feedback pathways activated by mTOR inhibition and the existence of two distinct mTOR complexes (mTORC1 and mTORC2) present challenges in developing effective inhibitors.

Purpose of the Study:

  • To explore the therapeutic potential of targeting the mTOR pathway in cancer, particularly in myeloma.
  • To investigate the role of dual mTORC1/mTORC2 inhibitors in overcoming resistance mechanisms associated with single-complex inhibitors.
  • To identify novel therapeutic targets within the mTOR pathway specific to myeloma.

Main Methods:

  • Review of preclinical studies on rapalogs and novel TORC1/TORC2 inhibitors in myeloma models.
  • Analysis of early-phase clinical trial data for mTOR inhibitors in relevant cancers.
  • Investigation of the role of DEPTOR as a potential therapeutic target in myeloma.

Main Results:

  • Preclinical studies demonstrate the efficacy of rapalogs and dual TORC1/TORC2 inhibitors in myeloma models.
  • Early clinical trials are underway, indicating progress in translating preclinical findings.
  • Up-regulated expression of DEPTOR in myeloma cells suggests its potential as a tumor-specific therapeutic target.

Conclusions:

  • Targeting both mTORC1 and mTORC2 complexes offers a promising strategy for cancer therapy, particularly in overcoming feedback-mediated resistance.
  • Dual mTOR inhibitors are advancing into clinical trials, showing potential for treating hematological malignancies like myeloma.
  • DEPTOR represents a novel, myeloma-specific therapeutic target that warrants further investigation for its role in restricting mTOR activity.

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...